Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2003
03/06/2003WO2003017769A1 Antimicrobial agent
03/06/2003WO2003017763A1 Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
03/06/2003WO2003002090B1 Immunopotentiator for mammary gland of dairy cows containing lactoferrin as an active ingredient
03/06/2003WO2003000729A3 Secreted polypeptide and their use in the treatment of bone disorders
03/06/2003WO2003000198A3 Selective neuronal nitric oxide synthase inhibitors
03/06/2003WO2002101021A3 Purification of human serum albumin
03/06/2003WO2002100844A3 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/06/2003WO2002095026A8 Method of proliferating terminal differentiated cells and recombinant vector therefor
03/06/2003WO2002094848A8 Treatment of mycobacterium tuberculosis with antisense oligonucleotides
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002089780A3 Antiviral compounds
03/06/2003WO2002088178A8 Antigens of group b streptococcus and corresponding dna fragments
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002086061A3 Vesicle-associated proteins
03/06/2003WO2002085447A3 Microprojection array having a beneficial agent containing coating
03/06/2003WO2002079459A3 Means for inhibiting proteolytical processing of parkin
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002074243A9 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
03/06/2003WO2002072767A3 Mammalian neuralized family transcriptional regulators and uses therefor
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002066511A3 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
03/06/2003WO2002064731A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
03/06/2003WO2002062845A3 Adhesion molecules
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002059264A3 Specific human antibodies for selective cancer therapy
03/06/2003WO2002056837A3 Inhibition of protein-phosphatases for the treatment of heart failure
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002053753A3 Novel human lipase and polynucleotides encoding the same
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002047671A3 Lactam compound to inhibit beta-amyloid peptide release or synthesis
03/06/2003WO2002044378A3 Wnt signalling assay, methods and uses thereof
03/06/2003WO2002043753A8 Remedies for chronic hepatitis b
03/06/2003WO2002043507A3 Nutrient supplements and methods for treating autism and for preventing the onset of autism
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002033083A3 Methods of using a human il-17-related polypeptide to treat disease
03/06/2003WO2002031151A3 Lipocalins
03/06/2003WO2002030982A3 Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
03/06/2003WO2002022801A3 Mammalian receptor genes and uses
03/06/2003WO2002022678A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/06/2003WO2002022080A9 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/06/2003WO2002020765A3 38646, a guanine nucleotide exchange factor and uses therefor
03/06/2003WO2002016430A3 Peptide with effects on cerebral health
03/06/2003WO2002012325A3 Suppressor gene
03/06/2003WO2002012281A9 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
03/06/2003WO2002010401A3 18431 and 32374, human protein kinase family members and uses therefor
03/06/2003WO2002007675A3 Omega-conopeptides
03/06/2003WO2002006478A8 Extracellular matrix protein
03/06/2003WO2002004423A8 Thrombin inhibitors comprising an aminoisoquinoline group
03/06/2003WO2002002602A9 Slgp protein and nucleic acid molecules and uses therefor
03/06/2003WO2001098343A9 Conserved diaphanous-related formin autoregulatory domain (dad)
03/06/2003WO2001096394A3 Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
03/06/2003WO2001096378A3 Human epithin-like serine protease
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003WO2001075105A9 Human leucine-rich repeat family member and uses thereof
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003WO2001072781A9 Human genes and expression products
03/06/2003WO2001066741A9 Kcnb: a novel potassium channel protein
03/06/2003WO2001066596A9 Human fgf-23 gene and gene expression products
03/06/2003WO2001062924A9 Human g protein-coupled receptors
03/06/2003WO2001055393A9 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
03/06/2003US20030046717 Isolated nucleic acid that encodes a Patched like transmembrane protein, functioning in male germ cell development, and as a potential tumor suppressor
03/06/2003US20030046716 Providing transgenic mammal whose somatic and germ cells comprise nucleic acid sequence encoding PDGF operably linked to promoter which directs expression into mammary gland epithelial cells and obtaining milk from animal
03/06/2003US20030046714 Anti-neovasculature preparations for cancer
03/06/2003US20030045943 Device for regeneration of articular cartilage and other tissue
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045830 Inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that gene by topically applying or injecting the chimeric oligonucleotide
03/06/2003US20030045704 Chromosome 17p-linked prostrate cancer susceptibility gene and a paralog and orthologous genes
03/06/2003US20030045693 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/06/2003US20030045691 Reshaped human anti-hm 1.24 antibody
03/06/2003US20030045690 Having a mean diameter of 200-2000 nm, obtained by solidification from a mixture comprising fibrinogen, thrombin and Factor XIII in an water in oil emulsion
03/06/2003US20030045688 Human interleukin-four induced protein
03/06/2003US20030045686 Mutein polypeptide for use in the treatment of hypoxia and ischemic related tissue damages
03/06/2003US20030045685 Nucleotide sequences coding polypeptide for use in the treatment of cancer, psoriasis, inflammatory bowel disease and hyperlipidemia
03/06/2003US20030045684 Polypeptide for use in humans therapeutics and diagnostics
03/06/2003US20030045682 Antibodies immunospecific for STEAP1
03/06/2003US20030045681 Antibody for use in the treatment of angiogenesis
03/06/2003US20030045680 Peptidic modulators of the androgen receptor
03/06/2003US20030045679 Peptide for use in the treatment of cancer and alzheimer's disease
03/06/2003US20030045678 Crystalline or crystal-like lipopeptide for use as bactericides
03/06/2003US20030045677 Isolation of glycoproteins from bovine milk
03/06/2003US20030045579 Compounds and compositions for delivering active agents
03/06/2003US20030045553 Peroxisome proliferator-activated receptor agonists (PPAR) for increasing insulin sensitivity in treatment of diabetes and Syndrome X
03/06/2003US20030045496 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
03/06/2003US20030045495 Method for selective expression of therapeutic genes by hyperthermia
03/06/2003US20030045494 Synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor
03/06/2003US20030045493 Oligonucleotide compositions and their use to induce differentiation of cells
03/06/2003US20030045492 Comprising contacting skin of the animal with a vector that expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.
03/06/2003US20030045491 Identification of cancerous cells and identifying antitumor drugs by detection of expression levels of tyrosine threonine kinase; inhibiting tumor growth (especially breast and colon cancer)by inhibiting activity of TTK
03/06/2003US20030045489 Administering anti-angiogenic FGF-19 polypeptides or an anti-angiogenic FGF-19 nucleic acid to inhibit angiogenesis; antitumor agents
03/06/2003US20030045488 Antisense oligonucleotides comprising universal and/or degenerate bases
03/06/2003US20030045487 Compound 8 to 50 nucleobases in length targeted to a 5' UTR, coding, 3' UTR or intron region of a nucleic acid molecule encoding Phospholipase A2, group IIA (synovial); specifically hybridizes with and inhibits expression
03/06/2003US20030045486 Amino-modified ribozymes
03/06/2003US20030045485 Reducing the viability of a proliferating mammalian cells such as cancer cells by increasing the level or activity of p53 in the cell.
03/06/2003US20030045484 Crystallizing amorphous daptomycin from a crystallization solution comprising a cation from a salt, a buffer, an organic precipitant, and a low molecular weight alcohol.
03/06/2003US20030045477 Peptides having antiangiogenic activity
03/06/2003US20030045476 Heart homing conjugates
03/06/2003US20030045475 Reducing the rate of islet cell infiltration by lymphocytes in a diabetes-susceptible mammal by administering a gonadotropin-releasing hormone antagonist.
03/06/2003US20030045474 Pharmaceutical compositions
1 ... 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 ... 3163